Search for other papers by Taísa A R Vicente in
Google Scholar
PubMed
Search for other papers by Ívina E S Rocha in
Google Scholar
PubMed
Search for other papers by Roberto Salvatori in
Google Scholar
PubMed
Search for other papers by Carla R P Oliveira in
Google Scholar
PubMed
Search for other papers by Rossana M C Pereira in
Google Scholar
PubMed
Search for other papers by Anita H O Souza in
Google Scholar
PubMed
Search for other papers by Viviane C Campos in
Google Scholar
PubMed
Search for other papers by Elenilde G Santos in
Google Scholar
PubMed
Search for other papers by Rachel D C Araújo Diniz in
Google Scholar
PubMed
Search for other papers by Eugênia H O Valença in
Google Scholar
PubMed
Search for other papers by Carlos C Epitácio-Pereira in
Google Scholar
PubMed
Search for other papers by Mario C P Oliveira in
Google Scholar
PubMed
Search for other papers by Andrea Mari in
Google Scholar
PubMed
Search for other papers by Manuel H Aguiar-Oliveira in
Google Scholar
PubMed
C Varricchio M . Serum levels of insulin-like growth factor-I (IGF1) and IGF-binding protein-3 in healthy centenarians: relationship with plasma leptin and lipid concentrations, insulin action, and cognitive function . Journal of Clinical
Search for other papers by A V Dreval in
Google Scholar
PubMed
Search for other papers by I V Trigolosova in
Google Scholar
PubMed
Search for other papers by I V Misnikova in
Google Scholar
PubMed
Search for other papers by Y A Kovalyova in
Google Scholar
PubMed
Search for other papers by R S Tishenina in
Google Scholar
PubMed
Search for other papers by I A Barsukov in
Google Scholar
PubMed
Search for other papers by A V Vinogradova in
Google Scholar
PubMed
Search for other papers by B H R Wolffenbuttel in
Google Scholar
PubMed
Mandarino L Kashyap S Belfort R DeFronzo RA . Effect of IGF-I on FFA and glucose metabolism in control and type 2 diabetic subjects . American Journal of Physiology. Endocrinology and Metabolism 2002 282 E1360 – E1368 . ( doi:10.1152/ajpendo
Search for other papers by Alexander A L Jorge in
Google Scholar
PubMed
Search for other papers by Thomas Edouard in
Google Scholar
PubMed
Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova, Genova, Italy
Search for other papers by Mohamad Maghnie in
Google Scholar
PubMed
Search for other papers by Alberto Pietropoli in
Google Scholar
PubMed
Search for other papers by Nicky Kelepouris in
Google Scholar
PubMed
Search for other papers by Alicia Romano in
Google Scholar
PubMed
Search for other papers by Martin Zenker in
Google Scholar
PubMed
Search for other papers by Reiko Horikawa in
Google Scholar
PubMed
factor I (IGF-I) level, and bone age. Adverse drug reactions (ADR), serious ADRs (SADR), and serious adverse events (SAE) were recorded for all patients throughout the duration of treatment. The GHLIQUID-4020 trial was a 4-year multicenter, randomized
Search for other papers by Rachel D C A Diniz in
Google Scholar
PubMed
Search for other papers by Renata M Souza in
Google Scholar
PubMed
Search for other papers by Roberto Salvatori in
Google Scholar
PubMed
Search for other papers by Alex Franca in
Google Scholar
PubMed
Search for other papers by Elenilde Gomes-Santos in
Google Scholar
PubMed
Search for other papers by Thiago O Ferrão in
Google Scholar
PubMed
Search for other papers by Carla R P Oliveira in
Google Scholar
PubMed
Search for other papers by João A M Santana in
Google Scholar
PubMed
Search for other papers by Francisco A Pereira in
Google Scholar
PubMed
Search for other papers by Rita A A Barbosa in
Google Scholar
PubMed
Search for other papers by Anita H O Souza in
Google Scholar
PubMed
Search for other papers by Rossana M C Pereira in
Google Scholar
PubMed
Search for other papers by Alécia A Oliveira-Santos in
Google Scholar
PubMed
Search for other papers by Allysson M P Silva in
Google Scholar
PubMed
Search for other papers by Francisco J Santana-Júnior in
Google Scholar
PubMed
Search for other papers by Eugênia H O Valença in
Google Scholar
PubMed
Search for other papers by Viviane C Campos in
Google Scholar
PubMed
Search for other papers by Manuel H Aguiar-Oliveira in
Google Scholar
PubMed
, accelerated atherosclerosis, and increased cardiovascular mortality (9) . AOGHD has been associated with NAFLD (10, 11, 12) . Some of the effects of GH are mediated by circulating IGF1, which is mostly of liver origin. IGF1 circulates bound to six IGF1
Search for other papers by Robert Rapaport in
Google Scholar
PubMed
Search for other papers by Jan M Wit in
Google Scholar
PubMed
Search for other papers by Martin O Savage in
Google Scholar
PubMed
in the child or parents has been identified. However, since the discovery that most genes associated with growth have no direct relationship with the GH–IGF-I axis ( 9 ), it appears more useful to think in terms of another conceptual framework for
Search for other papers by Kennett Sprogøe in
Google Scholar
PubMed
Search for other papers by Eva Mortensen in
Google Scholar
PubMed
Search for other papers by David B Karpf in
Google Scholar
PubMed
Search for other papers by Jonathan A Leff in
Google Scholar
PubMed
identified, including (i) supraphysiological elevations of GH and/or IGF-1, (ii) trough GH concentrations above normal physiological levels, (iii) fluctuating IGF-1 levels, (iv) elevated IGF-1 in the absence of GH bioactivity, (v) nonphysiological tissue
Dipartimento di Medicina Clinica e Chirurgia, Università Federico II, Naples, Italy
Search for other papers by Maria Cristina De Martino in
Google Scholar
PubMed
Search for other papers by Richard A Feelders in
Google Scholar
PubMed
Search for other papers by Claudia Pivonello in
Google Scholar
PubMed
Search for other papers by Chiara Simeoli in
Google Scholar
PubMed
Search for other papers by Fortuna Papa in
Google Scholar
PubMed
Search for other papers by Annamaria Colao in
Google Scholar
PubMed
Search for other papers by Rosario Pivonello in
Google Scholar
PubMed
Search for other papers by Leo J Hofland in
Google Scholar
PubMed
and drugs targeting the IGF pathway in ACCs. These results are in line with a recently published phase I study demonstrating that a subgroup (about 40%) of ACC patients treated with cixutumumab (IGF1R inhibitor) and temsirolimus (mTOR inhibitor
Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden
Search for other papers by Charlotte Höybye in
Google Scholar
PubMed
Search for other papers by Laia Faseh in
Google Scholar
PubMed
Department of Medicine, Karlstad Hospital, Karlstad, Sweden
Search for other papers by Christos Himonakos in
Google Scholar
PubMed
Search for other papers by Tomasz Pielak in
Google Scholar
PubMed
Search for other papers by Jesper Eugen-Olsen in
Google Scholar
PubMed
. Doses were individually titrated to insulin-like growth factor I (IGF-I) levels in age-matched healthy subjects. Clinical examinations and sampling of fasting routine blood tests were performed at scheduled visits to the clinic and in addition 2 mL serum
Search for other papers by Sumana Chatterjee in
Google Scholar
PubMed
Search for other papers by Emily Cottrell in
Google Scholar
PubMed
Search for other papers by Stephen J Rose in
Google Scholar
PubMed
Search for other papers by Talat Mushtaq in
Google Scholar
PubMed
Search for other papers by Avinaash V Maharaj in
Google Scholar
PubMed
Search for other papers by Jack Williams in
Google Scholar
PubMed
Search for other papers by Martin O Savage in
Google Scholar
PubMed
Search for other papers by Louise A Metherell in
Google Scholar
PubMed
Search for other papers by Helen L Storr in
Google Scholar
PubMed
.5 −2.5 OBSL1 Het c.2671A>G, p.T891A Missense Damaging Probably damaging 26.8 Uncertain significance 6 1.2 −4.4 −2.2 IGF1R Het c.109_123dupATCGACATCCGCAAC, p.I37_N41dup In-frame NK NK NK Uncertain significance 7
Departments of Endocrinology, Molecular Medicine and Surgery, Metabolism and Diabetes
Search for other papers by Lisa Arnetz in
Google Scholar
PubMed
Departments of Endocrinology, Molecular Medicine and Surgery, Metabolism and Diabetes
Search for other papers by Neda Rajamand Ekberg in
Google Scholar
PubMed
Departments of Endocrinology, Molecular Medicine and Surgery, Metabolism and Diabetes
Search for other papers by Kerstin Brismar in
Google Scholar
PubMed
Departments of Endocrinology, Molecular Medicine and Surgery, Metabolism and Diabetes
Search for other papers by Michael Alvarsson in
Google Scholar
PubMed
of Clinical Endocrinology and Metabolism 1994 78 960 – 967 . ( doi:10.1210/jcem.78.4.7512573 ). 15 Brugts MP van Duijn CM Hofland LJ Witteman JC Lamberts SW Janssen JA . Igf-I bioactivity in an elderly population: relation to